IPP NCI federally funded research and development center (ffrdc) contract to-f
Active Awarded
- Contract number
- 75N91025F00010
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,532,970
Award facts
- Contract value 100% obligated
- $2,532,970.00 Current and potential, with all options
- Completion date 45% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $2.53M delivery order contract to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., on September 5, 2025. This cost-plus-fixed-fee contract is structured as part of the IPP NCI Federally Funded Research and Development Center (FFRDC) contract vehicle and carries no small business set-aside designation. The work will be performed at Leidos Biomedical Research's facility in Frederick, Maryland, with an ultimate completion date of February 29, 2028. As an FFRDC contractor, Leidos Biomedical Research serves as a critical research and development partner for the National Cancer Institute and broader National Institutes of Health, providing comprehensive biomedical research support and facilities management services.
Leidos Biomedical Research Inc. has established extensive capabilities in cancer research, clinical trials support, advanced genetic research, and laboratory testing services through its prior contract work with NCI and affiliated agencies. The company's Frederick National Laboratory for Cancer Research has demonstrated expertise in complex interdisciplinary research including gene therapy development, high-resolution genotyping, and immunological investigations conducted in collaboration with leading academic institutions. This delivery order represents continued support for NCI's research mission, leveraging the contractor's established scientific infrastructure and technical expertise in federal biomedical research operations.
Quick answers
Who was awarded contract 75N91025F00010?
75N91025F00010 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 5, 2025.
How much is contract 75N91025F00010 worth?
The government has obligated $2,532,970 on 75N91025F00010.
Is contract 75N91025F00010 an order under another contract?
Yes. 75N91025F00010 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00010 competed?
The extent of competition for 75N91025F00010 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award